Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953873 · ClinicalTrials.gov registry record · Phase 4
Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients
A Phase 4 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT02953873: Completed Phase 4 study, sponsored by Medical University of South Carolina.
NCT02953873 is a Phase 4 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02953873, a Phase 4 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.
Primary Outcome
Difference in dose-normalized trough at steady state before and after conversion from tacrolimus IR to Astagraf XL®
Interventions
- DRUG Prednisone
- DRUG Mycophenolate mofetil
- DRUG Mycophenolate Sodium
- DRUG Tacrolimus Extended Release Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-05-05 |
| Est. Completion | 2018-12-14 |
| Phase | Phase 4 |
What the finished NCT02953873 record still lists
NCT02953873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT02953873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02953873 about?
NCT02953873 is a clinical study titled "Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients". Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.
What is the current status of trial NCT02953873?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2017-05-05. Estimated completion is 2018-12-14.
What interventions are being tested in trial NCT02953873?
The interventions under investigation include: Prednisone (DRUG), Mycophenolate mofetil (DRUG), Mycophenolate Sodium (DRUG), Tacrolimus Extended Release Capsule (DRUG).
Who is sponsoring clinical trial NCT02953873?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02953873's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI